NURIX THERAPEUTICS, INC. (NRIX) Payables and obligations
- Other obligations · latest quarter (USD): Value (m); Formula and calculation Total liabilities − borrowing debt − payables − total deferred revenue. Includes accruals, taxes, leases and other obligations; excludes the separately shown balances. Period ending 2026-05-31..
- Payables · latest quarter (USD): Value $12.21M; Formula and calculation Amounts owed to suppliers, reported accounts payable. Period ending 2026-05-31..
- Deferred revenue · latest quarter (USD): Value $19.30M; Formula and calculation Current and noncurrent customer contract obligations; payments received before revenue is earned. Period ending 2026-05-31..
- Other obligations · due within 1 year (USD): Value $1.30M; Formula and calculation Reported other current liabilities. Excludes separately reported debt, payables and current deferred revenue. The saved current-quarter facts do not separately disclose taxes, payroll, leases or accruals. Period ending 2026-05-31..
Payables and obligations
Overview →Financial period ending 2026-05-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Other obligations · latest quarter (USD) | (m) | Total liabilities − borrowing debt − payables − total deferred revenue. Includes accruals, taxes, leases and other obligations; excludes the separately shown balances. Period ending 2026-05-31. Calculation unavailable: missing inputs remain (m). |
| Payables · latest quarter (USD) | $12.21M | Amounts owed to suppliers, reported accounts payable. Period ending 2026-05-31. Reported amount: $12.21M |
| Deferred revenue · latest quarter (USD) | $19.30M | Current and noncurrent customer contract obligations; payments received before revenue is earned. Period ending 2026-05-31. $13.32M + $5.97M ≈ $19.30M |
| Other obligations · due within 1 year (USD) | $1.30M | Reported other current liabilities. Excludes separately reported debt, payables and current deferred revenue. The saved current-quarter facts do not separately disclose taxes, payroll, leases or accruals. Period ending 2026-05-31. Reported amount: $1.30M |
| Other obligations · due after 1 year (USD) | (m) | Reported other noncurrent liabilities minus the noncurrent deferred revenue they include (total customer contract obligations − current portion); a separately reported noncurrent deferred revenue line is not deducted. The saved current-quarter facts do not separately disclose taxes, leases or other accruals. Period ending 2026-05-31. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Total reported obligations | 132.91M USD | Liabilities |
| Borrowing debt | (m) | |
| Amounts owed to suppliers | 12.21M USD | Accounts Payable, Current |
| Total deferred revenue | 19.30M USD | Contract with Customer, Liability, Current · Contract with Customer, Liability, Noncurrent |
| Deferred revenue due within one year | 13.32M USD | Contract with Customer, Liability, Current |
| Deferred revenue due after one year | 5.97M USD | Contract with Customer, Liability, Noncurrent · Contract with Customer, Liability, Current |
| Reported other obligations due within one year | 1.30M USD | Other Liabilities, Current |
| Reported other noncurrent obligations | (m) | Other Liabilities, Noncurrent |
| Deferred revenue included in other noncurrent obligations | 0.00 USD | Contract with Customer, Liability, Current |
Other obligations breakdown
- Other obligations · due within 1 year (USD)
- $1.30M
- Other obligations · due after 1 year (USD)
- (m)
Bonds and commercial paper are already included in Total debt. Other obligations include taxes, accrued expenses and operating/finance leases. Category amounts below are the issuer’s own tagged balances at the same quarter end; untagged categories are not shown.
| Category | Quarter ending 2026-05-31 |
|---|---|
| Operating lease obligations | $58.14M |
These categories are parts of the combined obligations, not additional deductions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Other obligations | Payables | Deferred revenue | Short-term obligations | Long-term obligations | Total reported obligations (USD) | Borrowing debt (USD) | Deferred revenue due within one year (USD) | Deferred revenue due after one year (USD) | Reported other noncurrent obligations (USD) | Deferred revenue included in other noncurrent obligations (USD) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-31 | (m) | $12.21M | $19.30M | $1.30M | (m) | $132.91M | (m) | $13.32M | $5.97M | (m) | $0.00 |
| 2026-02-28 | (m) | $10.29M | $26.34M | $1.93M | (m) | $155.24M | (m) | $18.75M | $7.58M | (m) | $0.00 |
| 2025-11-30 | (m) | $11.21M | $27.59M | $2.10M | (m) | $149.39M | (m) | $17.58M | $10.01M | (m) | $0.00 |
| 2025-08-31 | (m) | $8.61M | $41.17M | $1.73M | (m) | $150.22M | (m) | $25.99M | $15.18M | (m) | $0.00 |
| 2025-05-31 | (m) | $5.95M | $49.06M | $1.04M | (m) | $143.95M | (m) | $27.42M | $21.64M | (m) | $0.00 |
| 2025-02-28 | (m) | $8.40M | $54.74M | $2.69M | (m) | $134.13M | (m) | $30.59M | $24.15M | (m) | $0.00 |
| 2024-11-30 | (m) | $11.48M | $64.57M | $2.27M | (m) | $142.35M | (m) | $38.36M | $26.21M | (m) | $0.00 |
| 2024-08-31 | (m) | $3.92M | $77.86M | $662.00K | (m) | $136.74M | (m) | $48.00M | $29.86M | (m) | $0.00 |
| 2024-05-31 | (m) | $2.81M | $85.44M | $1.00M | (m) | $140.34M | (m) | $46.77M | $38.67M | (m) | $0.00 |
| 2024-02-29 | (m) | $5.92M | $80.53M | $736.00K | (m) | $143.93M | (m) | $46.08M | $34.46M | (m) | $0.00 |
| 2023-11-30 | (m) | $6.40M | $93.12M | $751.00K | (m) | $155.10M | (m) | $48.10M | $45.02M | (m) | $0.00 |
| 2023-08-31 | (m) | $2.19M | $42.28M | $834.00K | (m) | $74.38M | (m) | $32.04M | $10.24M | (m) | $0.00 |
| 2023-05-31 | (m) | $4.53M | $58.75M | $1.24M | (m) | $90.70M | (m) | $44.06M | $14.68M | (m) | $0.00 |
| 2023-02-28 | (m) | $5.63M | $64.42M | $1.02M | (m) | $96.10M | (m) | $38.30M | $26.12M | (m) | $0.00 |
| 2022-11-30 | (m) | $5.06M | $73.61M | $1.50M | (m) | $113.06M | (m) | $37.63M | $35.97M | (m) | $0.00 |
| 2022-08-31 | (m) | $6.05M | $77.89M | $1.65M | (m) | $116.79M | (m) | $36.34M | $41.55M | (m) | $0.00 |
| 2022-05-31 | (m) | $6.14M | $87.18M | $2.24M | (m) | $127.57M | (m) | $41.32M | $45.86M | (m) | $0.00 |
| 2022-02-28 | (m) | $6.01M | $98.61M | $551.00K | (m) | $131.80M | (m) | $43.19M | $55.43M | (m) | $0.00 |
| 2021-11-30 | (m) | $6.65M | $100.23M | $659.00K | (m) | $134.47M | (m) | $41.21M | $59.02M | (m) | $0.00 |
| 2021-08-31 | (m) | $3.86M | $101.63M | $628.00K | $796.00K | $117.86M | (m) | $35.25M | $66.38M | $796.00K | $0.00 |
| 2021-05-31 | (m) | $5.41M | $105.88M | $601.00K | $837.00K | $119.80M | (m) | $33.76M | $72.12M | $837.00K | $0.00 |
| 2021-02-28 | (m) | $4.39M | $110.47M | $696.00K | $832.00K | $126.53M | (m) | $32.75M | $77.72M | $832.00K | $0.00 |
| 2020-11-30 | (m) | $3.41M | $93.48M | $700.00K | $850.00K | $106.07M | (m) | $32.80M | $60.69M | $850.00K | $0.00 |
| 2020-08-31 | (m) | $3.61M | $92.67M | $958.00K | $868.00K | $104.25M | (m) | $30.30M | $62.37M | $868.00K | $0.00 |
| 2019-11-30 | (m) | $1.60M | $45.30M | $309.00K | $1.74M | $53.57M | (m) | $9.61M | $35.69M | $1.74M | $0.00 |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |